Arcus Biosciences (RCUS) Net Equity Issued and Repurchased (2020 - 2025)

Arcus Biosciences' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $279.0 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $279.0 million; the TTM figure through Mar 2026 stood at $287.0 million (up 102.11% YoY), while the FY2025 annual figure was $429.0 million, up 88.16% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $279.0 million, up from $8.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $279.0 million in Q4 2025, with the low at -$235000.0 in Q4 2021.
• The 4-year median for Net Equity Issued and Repurchased is $81.0 million (2023), against an average of $112.8 million.
• Peak annual rise in Net Equity Issued and Repurchased reached 34151.17% in 2021, while the deepest fall reached 204.91% in 2021.
• Arcus Biosciences' Net Equity Issued and Repurchased stood at -$235000.0 in 2021, then jumped by 2227.66% to $5.0 million in 2023, then jumped by 4460.0% to $228.0 million in 2024, then grew by 22.37% to $279.0 million in 2025.
• Business Quant data shows RCUS's Net Equity Issued and Repurchased at $279.0 million in Q4 2025, $8.0 million in Q3 2025, and $142.0 million in Q1 2025.